4
Changes in Ownership
Axsome Therapeutics, Inc. Filed Acc 0001193125-26-264035
Chief Financial Officer sold 33,000 shares at $240.09 ($7,922,970)
- Chief Financial Officer acquired 33,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Pizzie Nick · Chief Financial Officer
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-06-09 | Exercise or conversion : show line 1 in the form 10b5-1 | +33,000 | $3.50 | $115,500 | 75,867 | D |
| 2026-06-09 | Sale : show line 2 in the form 10b5-1 | −33,000 | $240.09 | $7,922,970 | 42,867 | D |
| Open-market sales · 33,000 sh · avg $240.09 · $7,922,970 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2026-06-09 | Exercise or conversion : show line 3 in the form 10b5-1 Stock Option (Right to Buy) | −33,000 | 72,000 | D |
Loading xslF345X06/ownership.xml…